Fractalkine (CX3CL1) levels in patients with Beh莽et's disease and Neuro-Beh莽et's disease

详细信息	查看全文 | 推荐本文 |

• 作者：Irkec Ceyla^a ; ^{ceylairkec@yahoo.com} ; Teksut Kuz Tuba^a ; Adisen Esra^b ; Ozturk Banu^c ; Fidan Isil^d ; Gurer M. Ali^b ; Imir Turgut^d ; Bozkurt Banu^c
• 关键词：Behç ; et's disease ; Neuro-Behç ; et's disease ; Fractalkine (CX3CL1)
• 刊名：Journal of the Neurological Sciences
• 出版年：2012
• 期刊代码：178_0022510x
• 类别：med
• 出版时间：15 April, 2012
• 卷：315
• 期：1-2
• 页码：120-122
• 文件大小：194 K

摘要

Objective

The aim of the present study was to assess the role of CX3CL1 in patients with active and inactive Beh莽et's Disease (BD), Neuro-Beh莽et's Disease (NBD) and control subjects.

Methods

Fifty-six patients admitted to the BD and NBD Outpatient Clinics, and 30 healthy controls were enrolled in the study. Serum CX3CL1 levels were measured by an enzyme linked immunosorbent assay (ELISA).

Results

No significant difference was found between the serum CX3CL1 levels of control subjects, and patients with active and inactive BD or NBD, regardless of treatment.

Conclusion

To our knowledge, this is the first study analyzing CX3CL1 levels in patients with BD and NBD. Our results demonstrated that serum CX3CL1 levels were not changed in active and inactive BD and NBD. However, further large-scale studies are needed to confirm our results.